In addition, commercial HDAC inhibitors such as vorinostat have poor selectivity, which leads to the death of both cancer and normal cells and numerous side effects such as anemia, asthenia, nausea, fatigue, thirst, pneumonia, and deep vein thrombosis [30,31]. The gene discussed is HDAC9; the disease is cancer.